Results reported October 8, 2026 | NASDAQ: TLRY | Cannabis, beverage alcohol, wellness and distribution
The Quick Take
Tilray posted a record first-quarter revenue of $257.1M (+23%), but it was below the roughly $266M analysts expected. The loss was smaller than feared on an adjusted basis (adjusted loss of $0.02 per share versus about $0.18 expected), yet GAAP net loss widened to $40.0M ($0.32 per share) on non-cash charges. Free cash flow was negative $27.4M. Management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68M to $75M and leaned on diversification as the story. Growth is real, but it is acquisition-driven and profits remain thin.
Results
| Metric | Q1 FY2027 | Prior year / vs. expectations |
|---|---|---|
| Net revenue | $257.1M | +23% (from $209.5M); consensus about $266M |
| Gross profit | $77.5M | +35% (from $57.5M) |
| Gross margin | 30% | vs. 27% |
| Net loss | $40.0M ($0.32 per share) | vs. net income of $1.5M |
| Adjusted net loss | $3.0M ($0.02 per share) | vs. adjusted income of $3.4M; consensus about $(0.18) |
| Adjusted EBITDA | $9.2M | vs. $10.2M (absorbed about $1.7M of fuel surcharges) |
| Operating cash flow | $(16.5)M | vs. $(1.3)M |
| Free cash flow | $(27.4)M | Adjusted FCF $(23.4)M |
Segment Detail
| Segment | Revenue | Gross margin |
|---|---|---|
| Beverage | $101.5M, +82% (mainly BrewDog acquisition) | 41% (38%) |
| Cannabis | $56.1M, down from $64.5M | 39% (36%) |
| Distribution | $84.3M, +14% | 11% (11%) |
| Wellness | $15.3M, roughly flat | 29% (32%) |
EMEA revenue rose 71%, led by medical cannabis, beverages and pharmaceutical distribution.
Balance Sheet
Cash, restricted cash and marketable securities total $221.4M. Total debt fell by $42M year to date, and the company reports a net cash position. Convertible debentures of $59.2M are due within a year, and long-term debt is $118.0M.
Guidance
Fiscal 2027 adjusted EBITDA of $68M to $75M was reaffirmed, implying double-digit growth. Results are weighted to the second half, with the fourth quarter strongest. Management also pointed to a planned Carlsberg partnership to produce and sell its brands in the U.S. starting January 1, 2027. CEO Irwin Simon said, “We are no longer dependent on a single market or regulatory catalyst.”
Quality of the Quarter
Revenue growth is mostly bought: nearly all the beverage jump comes from BrewDog. Core cannabis revenue actually shrank about 13%, which is the segment investors most associate with the stock. Adjusted EBITDA slipped even as revenue rose 23%, so growth is not yet converting to profit. The better points are gross margin expansion in three of four segments and a net cash balance sheet.
Risks
- Cannabis revenue decline and price pressure.
- Heavy reliance on a back-half-weighted year to reach EBITDA guidance.
- Cash burn: negative operating and free cash flow.
- Integration risk from acquisitions such as BrewDog.
- Large non-cash charges that keep GAAP results negative.
- Regulatory uncertainty around U.S. cannabis rescheduling.
Recommendation: HOLD (Speculative)
Tilray has a stronger balance sheet and a more diversified base than a year ago, and the Carlsberg deal adds a catalyst. But the revenue miss, shrinking cannabis sales, falling EBITDA and cash burn mean the guidance depends on a strong second half. This is a speculative position only. Current holders can wait for Q2, and new buyers should size small or wait for evidence of positive free cash flow.
This is educational analysis, not personalized investment advice. Do your own research before investing.
Sources: Tilray Brands Q1 fiscal 2027 earnings release (Form 8-K, October 8, 2026); TipRanks earnings calendar for consensus estimates.
For educational purposes only, not investment advice.
#TradingTips #TradingSetup #trending #TradingDiscipline #stocktrading #StockInFocus #StockToWatch #US #USMarket #brent #GlobalMarketUpdates #DowJones #Nasdaq #NYSE #Tilray
Leave a comment